Nom du produit:2-hydroxy-2-pyridin-3-ylacetonitrile
IUPAC Name:2-hydroxy-2-(pyridin-3-yl)acetonitrile
- CAS:17604-74-9
- Formule moléculaire:C7H6N2O
- Pureté:95%+
- Numéro de catalogue:CM589837
- Poids moléculaire:134.14
Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:17604-74-9
- Formule moléculaire:C7H6N2O
- Point de fusion:-
- Code SMILES:C1=CC(=CN=C1)C(C#N)O
- Densité:
- Numéro de catalogue:CM589837
- Poids moléculaire:134.14
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- COBENFY
- Bristol Myers Squibb announced that the FDA has approved COBENFY® (xanomeline and trospium chloride). COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1 and M4 receptors in the brain without blocking D2 receptors. COBENFY® (xanomeline and trospium chloride), formerly KarXT, is an oral medication for the treatment of schizophrenia in adults. COBENFY combines xanomeline, a dual M1 - and M4 - preferring muscarinic receptor agonist, with trospium chloride, a muscarinic receptor antagonist that does not appreciably cross the blood-brain barrier, primarily acting in peripheral tissues. While the exact mechanism of action of COBENFY is unknown, its efficacy is thought to be due to the agonist activity of xanomeline at M1 and M4 muscarinic acetylcholine receptors in the central nervous system.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.